摘要
目的探讨紫杉醇联合顺铂新辅助化疗肺鳞癌的临床疗效。方法选取肺鳞癌患者60例作为研究对象,随机将其分为2组,每组30例。对照组患者直接接受单纯手术进行治疗,而研究组患者在经过紫杉醇联合顺铂进行新辅助化疗2~3周后,再接受手术进行治疗。对研究组患者进行新辅助化疗的临床疗效以及安全性进行统计分析,并于治疗前后对所有患者的生存质量进行问卷调查并统计分析,同时对所有患者进行为期2年的随访,对其术后的复发以及转移率以及生存率进行统计分析。结果研究组患者在经过新辅助化疗后,肿瘤显著减小,与化疗前比较,差异具有统计学意义(P<0.05)。化疗有效率Ⅲa期达到85.0%,Ⅲb期术前有效率只有30.0%,化疗总有效率为66.67%。化疗主要的毒副作用是消化和血液系统,但程度较轻,均可耐受。相比于对照组,研究组患者术后的复发以及转移率都明显降低,同时患者的生存率以及生存质量显著提高,且2组之间差异具有统计学意义(P<0.05)。结论紫杉醇联合顺铂新辅助化疗治疗肺鳞癌安全有效,可以减少术后转移以及复发的几率,提高患者的生存率和生存质量,值得临床推广。
Objective To investigate the clinical efficacy of neoadjuvant chemotherapy with paclitaxel and cisplatin for patients with squamous cell carcinoma. Methods 60 patients with squamous cell carcinoma who were diagnosed and treated in our hospital were selected as the subjects. Mainly patients with lung squamous cell carcinoma,were randomly divided into 2 groups,each group with 30 cases,the patients in the control group were treated with surgery alone,and the patients in the study group were treated with neoadjuvant chemotherapy with paclitaxel and cisplatin for 2 - 3 weeks. The study group of patients with neoadjuvant chemotherapy clinical efficacy and safety of statistical analysis,before and after treatment,the quality of life of all patients were investigated by questionnaire and statistical analysis. At the same time,all patients were followed up for 2 years,and their postoperative recurrence,metastasis rate and survival rate were statistically analyzed. Results After neoadjuvant chemotherapy,the tumor group was significantly reduced,the tumor size before and after chemotherapy were compared,the difference was statistically significant（ P〈0. 05）; The results of chemotherapy results showed that the effective rate of Ⅲ a patients reached85. 0%,the effective rate of stage Ⅲb was 30. 0%,the total effective rate was 66. 67%; The main side effects in chemotherapy were digestive and blood systems,but less severe,can be tolerable; Postoperative long-term results showed that compared with the control group,the study group patients postoperative recurrence and metastasis rates were significantly lower,while patients with significantly increased survival rate and quality of life,and the difference between the 2 groups was statistically significant（ P〈0. 05）. Conclusion Neoadjuvant chemotherapy with paclitaxel and cisplatin for patients with for lung squamous cell carcinoma is safe and effective,which reduce the chances of postoperative metastasis and recurrence,improve patient＇s survival rate and quality of life,it is worthy of clinical promotion.
作者
杨昌杰
杨莉
YANG Changjie;YANG Li(Jiangyou People＇s Hospital,Jiangyou,621700)
出处
《实用癌症杂志》
2018年第9期1442-1444,1464,共4页
The Practical Journal of Cancer
关键词
肺鳞癌
紫杉醇
顺铂
新辅助化疗
Lung squamous cell carcinoma
Paclitaxel
Cisplatin
Neoadjuvant chemotherapy
